MW 379.5 Da, Purity >98%. Chemosensitizing agent. Potent and selective BCRP inhibitor. Selective AKT inhibitor. Selectively reverses resistance to and potentiates mitoxantrone (ab145668), doxorubicin (ab120629) and topotecan (ab120388) in BCRP-transfected cells. Mycotoxin. Shows antiproliferative effects. Shows tremorgenic effects in vivo. .
ABC transporter, ABC15, ABCG2_HUMAN, ABCP, ATP binding cassette sub family G (WHITE) member 2, ATP binding cassette transporter G2, ATP-binding cassette sub-family G member 2, BCRP, BCRP 1, BMDP, Breast cancer resistance protein, CD338, CDw338, CDw338 antigen, EST157481, GOUT1, MGC102821, MRX, MXR, MXR1, Mitoxantrone resistance-associated protein, Multi drug resistance efflux transport ATP binding cassette sub family G (WHITE) member 2, Placenta specific MDR protein, Placenta-specific ATP-binding cassette transporter, UAQTL1
MW 379.5 Da, Purity >98%. Chemosensitizing agent. Potent and selective BCRP inhibitor. Selective AKT inhibitor. Selectively reverses resistance to and potentiates mitoxantrone (ab145668), doxorubicin (ab120629) and topotecan (ab120388) in BCRP-transfected cells. Mycotoxin. Shows antiproliferative effects. Shows tremorgenic effects in vivo. .
Soluble in DMSO to 10 mM.
Chemosensitizing agent. Potent and selective BCRP inhibitor. Selective AKT inhibitor. Selectively reverses resistance to and potentiates mitoxantrone (ab145668), doxorubicin (ab120629) and topotecan (ab120388) in BCRP-transfected cells. Mycotoxin. Shows antiproliferative effects. Shows tremorgenic effects in vivo.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab144258, Fumitremorgin C (Tryptoquivaline), Chemosensitizing agent
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com